

# ARUNA KAMINENI, PHD, MPH

## CURRICULUM VITAE

### CONTACT INFORMATION:

Kaiser Permanente Washington Health Research Institute

1730 Minor Ave., Suite 1600

Seattle, Washington 98101

phone: 206-287-2922

e-mail: Aruna.S.Kamineni@kp.org

webpage: <https://www.kpashingtonresearch.org/our-research/our-scientists/kamineni-aruna/>

### EDUCATION:

2010                    **PhD, Epidemiology**, University of Washington, Seattle, Washington

1997                    **MPH, Epidemiology**, University of Washington, Seattle, Washington

1993                    **BS, Molecular Biology, cum laude**, California State University,  
Sacramento, California

### PROFESSIONAL POSITIONS:

2018 – present        **Investigator I**, Kaiser Permanente Washington Health Research Institute,  
Kaiser Foundation Health Plan of Washington\*, Seattle, Washington

2014 – 2018          **Research Associate III**, Kaiser Permanente Washington Health Research  
Institute, Kaiser Foundation Health Plan of Washington\*, Seattle,  
Washington

2009 – 2014          **Research Associate II**, Group Health Research Institute\*, Seattle,  
Washington

2004 – 2009          **Research Scientist 4**, Collaborative Health Studies Coordinating Center,  
Department of Biostatistics, University of Washington, Seattle,  
Washington

1997 – 2003          **Research Assistant**, Fred Hutchinson Cancer Research Center, Seattle,  
Washington

1996 – 1997          **Graduate Intern**, Division of Alcoholism and Substance Abuse Services,  
Seattle-King County Department of Public Health, Seattle, Washington

*\*Kaiser Permanente acquired Group Health in February 2017, at which point Group Health Research Institute became Kaiser Permanente Washington Health Research Institute.*

- 1995 – 1996      **Research Assistant**, Arteriosclerosis Family Studies Unit, Department of Epidemiology, University of Washington, Seattle, Washington
- 1993 – 1995      **Research Associate**, Santa Cruz Biotechnology, Inc., Santa Cruz, California
- 1992 – 1993      **Laboratory Assistant II**, Division of Hematology and Oncology, University of California Davis Medical Center, Sacramento, California

**TEACHING HISTORY:**

- 2003              **Guest Lecturer**, Epidemiology Journal Club, University of Washington, Seattle, Washington
- 1998 – 2000      **Teaching Assistant**, Introduction to Epidemiology, Extended MPH Degree Program, University of Washington, Seattle, Washington
- 1999              **Guest Lecturer**, Epidemiology Journal Club, University of Washington, Seattle, Washington
- 1997 – 1999      **Teaching Assistant**, Applications of Epidemiologic Methods, Department of Epidemiology, University of Washington, Seattle, Washington
- 1997 – 1999      **Teaching Assistant**, Introduction to Epidemiology and Biostatistics, Graduate Certificate Program, Department of Health Services, University of Washington, Seattle, Washington
- 1998              **Teaching Assistant**, Descriptive Data Analysis and Interpretation, Graduate Certificate Program, Department of Health Services, University of Washington, Seattle, Washington

**HONORS, AWARDS, SCHOLARSHIPS:**

- 2018              Pacific Science Center Science Communication Fellowship and Scholarship Award
- 2016              Group Health Research Institute\* Morale Award, Honorable Mention
- 2016              Group Health Research Institute\* Award for Most Publications – 2015 (Research Associate)
- 2012              Group Health Research Institute\* Mentoring Award nominee
- 2011              HMO Research Network Early Career Investigator Award
- 2011              American Society of Preventive Oncology, abstract among top 14 at 35<sup>th</sup> Annual Meeting
- 2002 – 2003      National Institute of Health Cancer Epidemiology and Biostatistics Training Program, Pre-doctoral Training Award

*\*Kaiser Permanente acquired Group Health in February 2017, at which point Group Health Research Institute became Kaiser Permanente Washington Health Research Institute.*

1999	University of Washington School of Public Health and Community Medicine Outstanding Teaching Assistant
1996 – 1997	Kellogg Public Health Fellowship for Students of Color
1995 – 1996	National Institute of Health Cancer Epidemiology and Biostatistics Training Program, Pre-doctoral Training Award
1993	Cum laude, California State University, Sacramento

**ADVISING AND FORMAL MENTORING:**

2011 – 2013	Doctoral Committee and Reading Committee member – Alison Silvis Rustagi, PhD student in Epidemiology, University of Washington, School of Public Health and Community Medicine
-------------	--

**RESEARCH SUPPORT:**

**Active funding**

4/1/2018 – 3/31/2023	<b>Multiple Principal Investigator</b> – Multi-level Optimization of the Cervical Cancer Screening Process in Diverse Settings & Populations (METRICS), National Cancer Institute (1UM1CA221940-01: Haas, Kamineni, Skinner, Tiro), Total direct costs: \$3,018,897.
4/1/2018 – 3/31/2023	<b>Multiple Principal Investigator</b> – Optimizing Colorectal Cancer Screening Precision and Outcomes in Community-based Populations (PRECISE), National Cancer Institute (1UM1CA222035-01: Corley, Chubak, Halm, Kamineni, Skinner, Schottinger), Total direct costs: \$3,003,511.
8/1/2017 – 12/31/2018	<b>Co-Investigator and Cancer Cohort Lead</b> – Kaiser Permanente Research Bank. Kaiser Foundation Health Plan of Washington Community Benefit (Ralston).

**Completed**

9/5/2015 – 6/30/2019	<b>Co-Investigator</b> – Moderate Hypertension in Pregnancy: Safety and Effectiveness of Treatment. National Institute of Child Health and Human Development (R01 HD082141: Dublin).
11/1/2014 – 9/29/2018	<b>Site Principal Investigator</b> – Federal Hepatitis C Virus Test & Cure Project (HCV-TAC), Centers for Disease Control and Prevention, Total direct costs: \$404,842 (original Site Principal Investigator: Scholes).

*\*Kaiser Permanente acquired Group Health in February 2017, at which point Group Health Research Institute became Kaiser Permanente Washington Health Research Institute.*

6/1/2017 – 5/31/2018	<b>Co-Principal Investigator</b> – Population-Based Research Optimizing Screening Through Personalized Regimens (PROSPR): Studying Colorectal Cancer Effectiveness of Screening Strategies (SuCCESS) and Cervical Cancer Unit (CCU) Close-out funding (U54 CA163261: Chubak/Kamineni), Total direct costs: \$424,800.
1/1/2018 – 6/30/2018	<b>Principal Investigator</b> – HPV Boost Pilot Study, Fred Hutchinson Cancer Research Center, Total costs: \$10,036.
10/1/2017 – 12/31/2017	<b>Principal Investigator</b> – HPV Boost Pilot Study, Kaiser Permanente Washington Health Research Institute Development Fund (Kamineni), Total costs: \$16,083.
10/1/2017 – 12/31/2017	<b>Co-Investigator</b> – Sessile Serrated Polyp Study, Kaiser Permanente Washington Health Research Institute Development Fund (Chubak).
9/12/2016 – 7/31/2017	<b>Consultant</b> – The Efficacy of Sigmoidoscopy and Colonoscopy in Preventing Incidence of and Deaths from Colorectal Cancer. National Cancer Institute (HHSN261201600160M: Kamineni).
6/1/2014 – 5/31/2017	<b>Co-Principal Investigator</b> – Studying Colorectal Cancer: Effectiveness of Screening Strategies (SuCCESS) Cervical Cancer Unit (CCU). National Cancer Institute (U54 CA 163261-04S: Chubak/Kamineni), Total direct costs: \$811,431.
9/1/2011 – 5/31/2017	<b>Co-Investigator and Screening Process Documentation Unit Director</b> – Studying Colorectal Cancer: Effectiveness of Screening Strategies (SuCCESS). National Cancer Institute (U54 CA163261: Chubak).
4/22/2013 – 3/31/2017	<b>Co-Investigator</b> – A Cohort Study of Sessile Serrated Polyps and Subsequent Colorectal Neoplasia. National Cancer Institute (R01 CA168338: Newcomb).
8/1/2015 – 12/31/2016	<b>Principal Investigator</b> – ICD-10 Transition Preparation. Group Health Research Institute* (Kamineni), Total costs: \$91,349.
3/1/2013 – 7/31/2015	<b>Co-Investigator</b> – EPCs IV Task Order 4: EPC To Chubak. Agency for Healthcare Research and Quality (HSA290201200015i: Whitlock).
9/30/2008 – 8/31/2013	<b>Site Principal Investigator</b> – Effective Communication for Preventing and Responding to Oncology Adverse Events: Cancer Research Network Cancer Communication Research Center (CRN CCRC). National Cancer Institute (P20 CA137219: Dearing).

\*Kaiser Permanente acquired Group Health in February 2017, at which point Group Health Research Institute became Kaiser Permanente Washington Health Research Institute.

9/1/2012 – 8/31/2013	<b>Co-Investigator</b> – Multi-Center Study of Pancreatic Cancer Etiology (PACIFIC) Completion. Group Health Research Institute* (Rutter).
9/10/2008 – 7/31/2013	<b>Co-Investigator</b> – Long-Term Survivorship in Older Women with Early Stage Breast Cancer (BOW II). National Cancer Institute (R01 CA093772: Silliman).
9/1/2011 – 8/31/2012	<b>Site Principal Investigator</b> – Efficacy of cervical cancer screening to prevent cervical cancer mortality among women ages 55-79 years: a population-based, case-control study. National Cancer Institute (K05 CA092002: Weiss). Total direct costs: \$19,264.
9/30/2009-8/31/2012	<b>Co-Investigator</b> – Cancer Screening Effectiveness and Research in Community-based Healthcare (SEARCH). National Cancer Institute (UC2 CA148576: Buist/Doubeni).
1/15/1999-8/14/2015	<b>Epidemiologist/Analyst</b> – Multi-Ethnic Study of Atherosclerosis (MESA). National Heart Lung and Blood Institute (N01 HC95159: Kronmal).
9/1/2009-6/30/2013	<b>Epidemiologist/Analyst</b> – Determinants and Consequences of Diabetes in Older Adults. National Heart Lung and Blood Institute (R01 HL094555: Mukamal).
6/1/2008-5/31/2011	<b>Epidemiologist/Analyst</b> – Cardiovascular Health Study (CHS) – Transition Phase. National Heart Lung and Blood Institute (HHSN268200800007C: Arnold/Kronmal).
6/1/2005/-12/31/2008	<b>Epidemiologist/Analyst</b> – Diabetes and Cardiovascular Disease. AMGEN (639434 K3: Siscovick).
4/1/2001-3/31/2006	<b>Research Assistant</b> – HPV: Biology, Clinical Significance and Epidemiology – Project 1: Anogenital Cancer: Prevalence, Natural History and Risk Factors for Primary and Secondary Tumors (Daling). National Cancer Institute (P01 CA 42792: McDougall/Galloway).
9/30/2000-9/29/2002	<b>Research Assistant</b> – SEER Special Studies #7: Pregnancy Outcomes in Childhood Cancer Survivors (Mueller). National Cancer Institute (N01 CN 67009: Thomas).
9/29/1999-8/31/2002	<b>Co-Investigator</b> – Cervical Cancer Screening Efficacy in Older Women. National Cancer Institute (R03 CA 84540-01: Weiss). Total direct costs: \$99,970.

**BIBLIOGRAPHY:**

*\*Kaiser Permanente acquired Group Health in February 2017, at which point Group Health Research Institute became Kaiser Permanente Washington Health Research Institute.*

## Peer-reviewed research articles

1. Doria-Rose VP, **Kamineni A**, Barrett MJ, Ko C, Weiss NS. Case-control studies of the efficacy of screening tests that seek to prevent cancer incidence: can we utilize administrative claims data that do not provide information regarding test indication? *Am J Epidemiol*. In press.
2. Chubak J, McLerran DF, Zheng Y, Singal AG, Corely DA, Doria-Rose VP, Doubeni CA, **Kamineni A**, Haas JS, Halm EA, Skinner CS, Zauber AG, Wernli KJ, Beaber EF. Receipt of Colonoscopy Following Diagnosis of Advanced Adenomas: An Analysis within Integrated Healthcare Delivery Systems. *Cancer Epidemiol Biomarkers Prev* 2018 Nov 20.
3. **Kamineni A**, Tiro JA, Beaber EF, Silverberg MJ, Wheeler CM, Chao CR, Chubak J, Skinner CS, Corley DA, Kim JJ, Balasubramanian BA, Doria-Rose VP. Cervical Cancer Screening Research in the PROSPR I Consortium: Rationale, Methods, and Baseline Findings from a U.S. Cohort. *Int J Cancer* 2018 Oct 24.
4. Selby K, Jensen CD, Zhao WK, Chubak J, Halm EA, Skinner CS, **Kamineni A**, Lee JK, Schottinger JE, Contreras R, Ghai NR, Doubeni CA, Levin TR, Corley DA. Influence of varying quantitative fecal immunochemical test cut-offs on sensitivity and specificity for colorectal cancer detection: a community-based cohort study. *Ann Intern Med*. 2018 Oct 2;169(7):439-447.
5. Mazor KM, **Kamineni A**, Roblin DW, Anau J, Robinson BE, Dunlap B, Firreno C, Gallagher TH. Encouraging patients to speak up about problems in cancer care. *J Patient Saf*. 2018 Jun 27.
6. Singal AG, Corley DA, **Kamineni A**, Garcia M, Zheng Y, Doria-Rose PV, Quinn VP, Jensen CD, Chubak J, Tiro J, Doubeni CA, Ghai NR, Skinner CS, Wernli K, Halm EA. Patterns and predictors of repeat fecal immunochemical and occult blood test screening in four large health care systems in the United States. *Am J Gastroenterol*. 2018 Feb 27.
7. Hubbard RA, Johnson E, Chubak J, Wernli KJ, **Kamineni A**, Bogart A, Rutter CM. Accounting for misclassification in electronic health records-derived exposures using generalized linear finite mixture models. *Health Serv Outcomes Res Methodol*. 2017 Jun; 17(2):101-112.
8. Balasubramanian BA, Garcia MP, Corley DA, Doubeni CA, Haas JS, **Kamineni A**, Quinn VP, Wernli K, Zheng Y, Skinner CS. Racial/ethnic differences in obesity and comorbidities between safety-net- and non safety-net integrated health systems. *Medicine* (Baltimore). 2017 Mar; 96(11):e6326.
9. Habbema D, Weinmann S, Arbyn M, **Kamineni A**, Williams AE, de Kok IM, van Kemenade F, Field TS, van Rosmalen J, Brown M. Harms of Cervical Cancer Screening in the United States and the Netherlands. *Int J Cancer*. 2016 Nov 16.
10. Zhang M, Wang Z, Obazee O, et al. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. *Oncotarget*. 2016 October 11;7(41):66328-66343.

11. Shortreed SM, Johnson EJ, Rutter CM, **Kamineni A**, Wernli KJ, Chubak J. Cohort restriction based on prior enrollment: examining potential biases in estimating cancer and mortality risk. *Observational Studies*. 2016 Aug; 2:51-64.
12. Klabunde CN, Zheng Y, Quinn VP, Beaver EF, Rutter CM, Halm EA, Chubak J, Doubeni CA, Haas JS, **Kamineni A**, Schapira M, Vacek PM, Garcia MP, Corley DA: PROSPR Consortium. Influence of age and comorbidity on completion of colorectal cancer screening in the elderly. *Am J Prev Med*. 2016 Sep; 51(3):e67-75.
13. Chubak J, Whitlock EP, Williams SB, **Kamineni A**, Burda BU, Buist DSM, Anderson ML. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2016 Jun 21;164(12):814-25.
14. Corley DA, Haas JS, Kobrin S. Reducing variation in the “standard of care” for cancer screening: Recommendations from the PROSPR Consortium. *JAMA*. 2016 May 17;315(19):2067-8.
15. Chubak J, Garcia MP, Burnett-Hartman A, Zheng Y, Corley DA, Halm EA, Singal AG, Klabunde CN, Doubeni CA, **Kamineni A**, Levin TR, Schottinger JE, Green BB, Quinn VP, Rutter CM. Time to colonoscopy after positive fecal blood test in four U.S. healthcare systems. *Cancer Epidemiol Biomarkers Prev*. 2016 Feb;25(2):344-50.
16. Tosteson AN, Beaver EF, Tiro J, Kim J, McCarthy AM, Quinn VP, Doria-Rose VP, Wheeler CM, Barlow WE, Bronson M, Garcia M, Corley DA, Haas JS, Halm EA, **Kamineni A**, Rutter CM, Tosteson TD, Trentham-Dietz A, Weaver DL; PROSPR consortium. Variation in Screening Abnormality Rates and Follow-Up of Breast, Cervical and Colorectal Cancer Screening within the PROSPR Consortium. *J Gen Intern Med*. 2016 Apr;31(4):372-9.
17. Sampson JN, Wheeler WA, Yeager M, et al. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. *J Natl Cancer Inst*. 2015 Oct 12;107(12):djv279.
18. Adams KF, Johnson EA, Chubak J, **Kamineni A**, Doubeni CA, Buist DS, Williams AE, Weinmann S, Doria-Rose VP, Rutter CM. Development of an Algorithm to Classify Colonoscopy Indication from Coded Health Care Data. *eGEMS (Wash DC)*. 2015 May 18;3(1):1171.
19. Weinmann S, Williams AE, **Kamineni A**, Buist DS, Masterson EE, Stout NK, Stark A, Ross TR, Owens CL, Field TS, Doubeni CA. Cervical cancer screening and follow-up in 4 geographically diverse US health care systems, 1998 through 2007. *Cancer*. 2015 Sep 1;121(17):2976-83.
20. Beaver EF, Kim JJ, Schapira MM, Tosteson AN, Zauber AG, Geiger AM, **Kamineni A**, Weaver DL, Tiro JA; Population-based Research Optimizing Screening through Personalized Regimens Consortium. Unifying screening processes within the PROSPR consortium: a conceptual model for breast, cervical, and colorectal cancer screening. *J Natl Cancer Inst*. 2015 May 7;107(6):djv120.

21. Arem H, Yu K, Xiong X, Moy K, et al. Vitamin D metabolic pathway genes and pancreatic cancer risk. *PLoS One*. 2015 Mar 23;10(3):e0117574.
22. Rutter CM, Greenlee RT, Johnson E, Stark A, Weinmann S, **Kamineni A**, Adams K, Doubeni CA. Prevalence of colonoscopy before age 50. *Prev Med*. 2015 Mar;72:126-9.
23. Chubak J, Hubbard RA, Johnson E, **Kamineni A**, Rutter CM. Assessing the effectiveness of a cancer screening test in the presence of another screening modality. *J Med Screen*. 2015 Jun;22(2):69-75.
24. Owens CL, Buist DS, Peterson D, **Kamineni A**, Weinmann S, Ross T, Williams AE, Stark A, Adams KF, Doubeni CA, Field TS. Follow-up and clinical significance of unsatisfactory liquid-based Papanicolaou tests. *Cancer Cytopathol*. 2015 Jan;123(1):59-65.
25. Wolpin BM, Rizzato C, Kraft P, et al. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. *Nat Genet*. 2014 Sep;46(9):994-1000.
26. Wang Z, Zhu B, Zhang M, et al. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. *Hum Mol Genet*. 2014 Dec 15;23(24):6616-33.
27. Tiro JA, **Kamineni A**, Levin TR, Zheng Y, Schottinger JS, Rutter CM, Corley DA, Skinner CS, Chubak J, Doubeni CA, Halm EA, Gupta S, Wernli KJ, Klabunde C. The colorectal cancer screening process in community settings: a conceptual model for the population-based research optimizing screening through personalized regimens consortium. *Cancer Epidemiol Biomarkers Prev*. 2014 Jul;23(7):1147-58.
28. Wernli KJ, Hubbard RA, Johnson E, Chubak J, **Kamineni A**, Green BB, Rutter CM. Patterns of colorectal cancer screening uptake in newly eligible men and women. *Cancer Epidemiol Biomarkers Prev*. 2014 Jul;23(7):1230-7.
29. Rustagi AS, **Kamineni A**, Weinmann S, Reed SD, Newcomb PA, Etzioni RB, Weiss NS. Cervical screening and cervical cancer death among older women: a population-based, case-control study. *Am J Epidemiol*. 2014 May 1;179(9):1107-14.
30. Haque R, Prout M, Geiger AM, **Kamineni A**, Thwin SS, Avila C, Silliman RA, Quinn V, Yood MU. Comorbidities and cardiovascular disease risk in older breast cancer survivors. *Am J Manag Care*. 2014;20(1):86-92.
31. Johnson KE, **Kamineni A**, Fuller S, Olmstead D, Wernli KJ. How the provenance of electronic health record data matters for research: a case example using system mapping. *eGEMs*. (Wash DC). 2014 Apr 16;2(1):1058.
32. Austin MA, Kuo E, Van Den Eeden SK, Mandelson MT, Brentnall TA, **Kamineni A**, Potter JD. Family history of diabetes and pancreatic cancer as risk factors for pancreatic cancer: The PACIFIC study. *Cancer Epidemiol Biomarkers Prev*. 2013 Oct; 22(10):1913-7.
33. Rustagi AS, **Kamineni A**, Weiss NS. Point: Cervical cancer screening guidelines should consider observational data on screening efficacy in older women. *Am J Epidemiol*. 2013 Oct 1; 178(7):1020-2.

34. Rustagi AS, **Kamineni A**, Weiss NS. Reponse to counterpoint: Efficacy of cervical cancer screening in older women. *Am J Epidemiol*. 2013 Oct 1; 178(7):1027.
35. **Kamineni A**, Weinmann S, Shy KK, Glass AG, Weiss NS. Efficacy of screening in preventing cervical cancer among older women. *Cancer Causes Control*. 2013 Sep; 24(9):1653-60.
36. Owens CL, Peterson D, **Kamineni A**, Buist DS, Weinmann S, Ross TR, Williams AE, Stark A, Adams KF, Field TS. Effects of transitioning from conventional methods to liquid-based methods on unsatisfactory Papanicolaou tests: Results from a multicenter US study. *Cancer Cytopathol*. 2013 Oct; 121(10):568-75.
37. Pawloski PA, Geiger AM, Haque R, **Kamineni A**, Fouayzi H, Ogarek J, Petersen HV, Bosco JLF, Thwin SS, Silliman RA, Field TS. Fracture risk in older, long-term survivors of early-stage breast cancer. *J Am Geriatr Soc*. 2013 Jun;61(6):888-95.
38. Chubak J, Rutter CM, **Kamineni A**, Johnson EA, Stout NK, Weiss NS, Doria-Rose VP, Doubeni CA, Buist DS. Measurement in comparative effectiveness research. *Am J Prev Med*. 2013 May; 44(5):513-9.
39. Doubeni CA, Weinmann S, Adams K, **Kamineni A**, Buist DS, Ash AS, Rutter CM, Doria-Rose VP, Corley DA, Greenlee RT, Chubak J, Williams A, Kroll-Desrosiers AR, Johnson E, Webster J, Richert-Boe K, Levin TR, Fletcher RH, Weiss NS. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. *Ann Intern Med*. 2013 Mar 5; 158(5 Pt 1):312-20.
40. **Kamineni A**, Anderson ML, White E, Taplin SH, Porter P, Ballard-Barbash R, Malone K, Buist DS. Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population. *Cancer Causes and Control*. 2013 Feb; 24(2):305-12.
41. Zieman SJ, **Kamineni A**, Ix JH, Barzilay J, Djoussé L, Kizer JR, Biggs ML, de Boer IH, Chonchol M, Gottdiener JS, Selvin E, Newman AB, Kuller LH, Siscovick DS, Mukamal KJ. Hemoglobin a1c and arterial and ventricular stiffness in older adults. *PLoS One*. 2012; 7(10):e47941.
42. Haque R, Yood MU, Geiger AM, **Kamineni A**, Avila CC, Shi J, Silliman RA, Quinn VP. Long-term safety of radiotherapy and breast cancer laterality in older survivors. *Cancer Epidemiol Biomarkers Prev*. 2011 Oct; 20(10):2120-6.
43. Strotmeyer ES, **Kamineni A**, Cauley JA, Robbins JA, Fried LF, Siscovick DS, Harris TB, Newman AB. Potential explanatory factors for higher incident hip fracture risk in older diabetic adults. *Curr Gerontol Geriatr Res*. 2011; 2011:979270.
44. Nelson TL, **Kamineni A**, Psaty B, Cushman M, Jenny NS, Hokanson J, Furberg C, Mukamal KJ. Lipoprotein-associated phospholipase A(2) and future risk of subclinical disease and cardiovascular events in individuals with type 2 diabetes: the Cardiovascular Health Study. *Diabetologia*. 2011 Feb; 54(2):329-33.

45. Criqui MH, **Kamineni A**, Allison MA, Ix JH, Carr JJ, Cushman M, Detrano R, Post W, Wong ND. Risk Factor Differences for Aortic Versus Coronary Calcified Atherosclerosis. The Multiethnic Study of Atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2010 Nov; 30(11):2289-96.
46. Djoussé L, **Kamineni A**, Nelson TL, Carnethon M, Mozaffarian D, Siscovick DS, Mukamal, KJ. Egg consumption and risk of type 2 diabetes in older adults. *Am J Clin Nutr*. 2010 Aug; 92(2):422-7.
47. Fowler-Brown AG, de Boer IH, Catov JM, Carnethon MR, **Kamineni A**, Kuller LH, Siscovick DS, Mukamal KJ. Parity and the Association with Diabetes in Older Women. *Diabetes Care*. 2010 Aug; 33(8):1778-82.
48. Aboyans V, **Kamineni A**, Allison M, McDermott MM, Crouse JR, Ni H, Szklo M, Criqui MH. The epidemiology of subclavian stenosis and its association with markers of subclinical atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA). *Atherosclerosis*. 2010 Jul; 211(1):266-70.
49. Allison MA, Aboyans V, Granston T, McDermott MM, **Kamineni A**, Ni H, Criqui MH. The relevance of different methods of calculating the ankle-brachial index: The Multi-Ethnic Study of Atherosclerosis. *Am J Epidemiol*. 2010 Feb 1; 171(3):368-76.
50. Chow EJ, **Kamineni A**, Daling JR, Fraser A, Wiggins CJ, Mineau GP, Hamre MR, Severson RK, Drews-Botsch C, Mueller BA. Reproductive outcomes in male childhood cancer survivors: a linked cancer-birth registry analysis. *Arch Pediatr Adolesc Med*. 2009 Oct; 163(10):887-94.
51. Mueller BA, Chow EJ, **Kamineni A**, Daling JR, Fraser A, Wiggins CL, Mineau GP, Hamre MR, Severson RK, Drews-Botsch C. Pregnancy outcomes in female childhood and adolescent cancer survivors: a linked cancer-birth registry analysis. *Arch Pediatr Adolesc Med*. 2009 Oct; 163(10):879-86.
52. Mitchell CT, **Kamineni A**, Palmas W, Cushman M. Tissue factor pathway inhibitor, vascular risk factors and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. *Atherosclerosis*. 2009 Nov; 207(1): 77-83.
53. Mozaffarian D, **Kamineni A**, Carnethon M, Djoussé L, Mukamal KJ, Siscovick DS. Lifestyle Risk Factors and New-Onset Diabetes Mellitus in Older Adults: the Cardiovascular Health Study. *Arch Intern Med*. 2009 Apr 27; 169(8):798-807.
54. Mozaffarian D, **Kamineni A**, Prineas RJ, Siscovick DS. Metabolic Syndrome and Mortality in Older Adults: the Cardiovascular Health Study. *Arch Intern Med*. 2008 May 12; 168(9):969-78.
55. Wong TY, **Kamineni A**, Klein R, Sharrett AR, Klein BEK, Siscovick DS, Cushman M, Duncan BB. Quantitative retinal venular caliber and risk of cardiovascular disease in older persons: the Cardiovascular Health Study. *Arch Intern Med*. 2006 Nov 27; 166(21):2388-94.

56. Mueller BA, Simon MS, Deapen D, **Kamineni A**, Malone KE, Daling JR. Childbearing and survival after breast carcinoma in young women. *Cancer*. 2003 Sep 15; 98(6):1131-40.
57. **Kamineni A**, Williams MA, Schwartz SM, Cook LS, Weiss NS. The incidence of gastric carcinoma in Asian migrants to the United States and their descendants. *Cancer Causes and Control*. 1999 Feb; 10(1):77-83.

### Peer-reviewed scholarly publications

Chubak J, **Kamineni A**, Buist DSM, Anderson ML, Whitlock EP. Aspirin Use for the Prevention of Colorectal Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep.

### Manuscripts under review

1. Burnett-Hartman AN, **Kamineni A**, Corley DA, Singal AG, Halm EA, Rutter CM, Chubak J, Lee JK, Doubeni CA, Inadomi JM, Doria-Rose VP, Zheng Y. Colonoscopy indication algorithm performance across diverse healthcare systems in the PROSPR Consortium.
2. Burnett-Hartman AN, Chubak J, Hua X, Ziebell R, **Kamineni A**, Zhu L, Upton MP, Hardikar S, Newcomb PA. The association between colorectal sessile serrated adenomas/polyps and subsequent advanced colorectal neoplasia.
3. Ko C, Doria-Rose VP, Barrett MJ, **Kamineni A**, Enewold L, Weiss NS. Screening colonoscopy and flexible sigmoidoscopy for reduction of colorectal cancer incidence.
4. Ko C, Doria-Rose VP, Barrett MJ, **Kamineni A**, Enewold L, Weiss NS. Screening colonoscopy and flexible sigmoidoscopy for reduction of colorectal cancer mortality.

### Manuscripts in preparation

1. **Kamineni A**, Blasi PR, Gundersen GD, Oliver M, Galloway DA, Madeleine MM. Barriers to human papillomavirus vaccine series completion in an insured population: results from a pilot study.
2. **Kamineni A**, Harding BN, Gundersen GD, Oliver M, Graham V, Chubak J. Validation of claims data for identification of cervical biopsies and excisions in a mixed-model healthcare system.
3. **Kamineni A**, Gundersen GD, Oliver M. Anal cytology testing and follow-up among HIV+ patients in an integrated healthcare system.
4. Wernli KJ, **Kamineni A**, Ichikawa L, Johnson E, Shortreed SM, Green BB, Chubak J, Rutter CM. Patterns of colorectal cancer screening with stool tests in U.S. adults.
5. Tiro JA, **Kamineni A**, Chao CR, Wheeler CM, Doria-Rose VP, Silverberg MJ, Pruitt SL, Kim JJ, Winer RL, Beaber EF, Chubak J, Corley DA, Quinn VP, Kobrin S. Characterizing HPV

vaccine dosing patterns among young adult women in the PROSPR I Cervical Consortium.

## CONFERENCES AND SYMPOSIA

### Oral Presentations

1. **Kamineni A**, Blasi PR, Gundersen GD, Oliver M, Galloway DA, Madeleine MM. Barriers to human papillomavirus vaccine series completion in an insured population: results from a pilot study. Increasing HPV Vaccination in the United States: A Collaboration of NCI-funded Cancer Centers, 2018 Consortium Meeting, June 7-8, 2018, Salt Lake City, Utah.
2. Wernli KJ, Hubbard R, Johnson E, Chubak J, **Kamineni A**, Rutter CM. Patterns of colorectal cancer screening uptake in men and women newly-eligible for screening. American Society for Preventive Oncology, 37<sup>th</sup> Annual Meeting, Memphis, TN, March 2013.
3. Wernli KJ, Hubbard R, Johnson E, Chubak J, **Kamineni A**, Rutter CM. Patterns of colorectal cancer screening uptake in men and women newly-eligible for screening. 19<sup>th</sup> Annual HMO Research Network Conference, April 16-18, 2013, San Francisco, California.
4. Haque R, Prout M, Geiger AM, **Kamineni A**, Thwin SS, Avila CC, Silliman RA, Quinn VP, Yood MU. Impact of Comorbidities on Cardiovascular Disease Risk in Older Breast Cancer Survivors and Age-Matched Comparisons. 18<sup>th</sup> Annual HMO Research Network Conference, April 29-May 2, 2012, Seattle, Washington.
5. **Kamineni A**, Weinmann S, Shy KK, Mandelson MT, Glass AG, Weiss NS. Cervical Cancer Screening Efficacy in Older women. 17<sup>th</sup> Annual HMO Research Network Conference, Plenary, March 23-25, 2011, Boston, Massachusetts.
6. **Kamineni A**, Weinmann S, Shy KK, Mandelson MT, Glass AG, Weiss NS. Cervical Cancer Screening Efficacy in Older women. American Society of Preventive Oncology. 35<sup>th</sup> Annual Meeting, March 5-8, 2011, Las Vegas, Nevada.

### Poster Presentations

1. **Kamineni A**, Tiro JA, Beaber EF, Silverberg MJ, Wheeler CM, Chao CR, Chubak J, Skinner CS, Corley DA, Kim JJ, Balasubramanian BA, Doria-Rose VP. Cervical Cancer Screening Research in the PROSPR I Consortium: Rationale, Methods, and Baseline Findings from a U.S. Cohort. International Papillomavirus Conference, October 2-6, 2018, Sydney, Australia.
2. **Kamineni A**, Blasi PR, Gundersen GD, Oliver M, Galloway DA, Madeleine MM. Barriers to Human Papillomavirus Vaccine Series Completion in an Insured Population: Results from

- a Pilot Study. International Papillomavirus Conference, October 2-6, 2018, Sydney, Australia.
3. Burnett-Hartman AN, Chubak J, Hua X, **Kamineni A**, Ziebell R, Hardikar S, Newcomb PA. The Association Between Sessile Serrated Adenomas/Polyps and Subsequent Advanced Colorectal Neoplasia. Digestive Disease Week. June 2-5, 2018, Washington, DC.
  4. **Kamineni A**, Gundersen G, Oliver M, Madziwa L, Graham V. Cervical Pathology Data Capture in a Mixed-Model Healthcare Delivery System. Health Care Systems Research Network Conference. April 11-13, 2018, Minneapolis, Minnesota.
  5. Wernli KJ, **Kamineni A**, Johnson E, Shortreed SM, Green BB, Chubak J, Rutter CM. Current patterns of colorectal cancer screening in an insured population. American Society for Preventive Oncology Conference, March 2016, Columbus, Ohio.
  6. Wernli KJ, Hubbard RA, Johnson E, Chubak J, **Kamineni A**, Green BB, Rutter CM. Patterns of colorectal cancer screening uptake in newly-eligible men and women. International Cancer Screening Network Conference. 2015, Rotterdam, The Netherlands.
  7. Chubak J, Garcia M, Burnett-Hartman A, Zheng Y, Halm EA, Corley DA, **Kamineni A**, Singal AG, Green BB, Doubeni CA, Klabunde CN, Rutter CM. Factors associated with time to colonoscopy after a positive fecal occult blood test. American Society of Preventive Oncology Conference. 2015, Birmingham, Alabama.
  8. **Kamineni A**, Wheeler CM, Tiro JA, Silverberg MJ, Chao CR, Kim JJ, Thornquist M, Doria-Rose VP. Cervical cancer screening research in the PROSPR consortium. HMO Research Network Conference, March 11-13, 2015, Long Beach, California.
  9. **Kamineni A**, Wheeler CM, Tiro JA, Silverberg MJ, Chao CR, Kim JJ, Thornquist M, Doria-Rose VP. Cervical cancer screening research in the PROSPR consortium. 6<sup>th</sup> PROSPR Scientific Meeting, October 20-22, 2014, Bethesda, Maryland.
  10. **Kamineni A**, Halgrim S, Gundersen G, Fuller S, Hart G, Carrell D, Rutter CM. Coordinating heterogeneous data and mixed collection methods to support population-based cancer research. 6<sup>th</sup> PROSPR Scientific Meeting, October 20-22, 2014, Bethesda, Maryland.
  11. Burnett-Hartman AN, Chubak J, **Kamineni A**, Ziebell R, Upton MP, Zhu L-C, Newcomb A. Short-term risk of colorectal cancer in colonoscopy patients with sessile serrated polyps. American Society of Preventive Oncology Conference. 2014, Arlington, Virginia.
  12. Halgrim S, Reeh S, Kelem R, Wong R, **Kamineni A**, Immanuel V, Pattilo C, Pardee R, Carrell D, Rutter C. Organization-wide collaboration to convert binary clinical notes to research-ready text. HMO Research Network Conference, April 1-3, 2014, Phoenix, Arizona.
  13. Mazor K, Roblin D, **Kamineni A**, Greene S, Reid R, Anau J, Robinson B, Gallagher T. Encouraging patients to report concerns: Development and pilot testing of the we want to know campaign. HMO Research Network Conference, April 16-18, 2013, San Francisco, California.

14. Wernli K, Hubbard R, Johnson E, Chubak J, **Kamineni A**, Rutter C. Patterns of colorectal cancer testing in men and women newly eligible for screening. HMO Research Network Conference, April 16-18, 2013, San Francisco, California.
15. **Kamineni A**, Halgrim S, Gundersen G, Fuller S, Hart G, Carrell D, Rutter CM. Coordinating heterogeneous data and mixed collection methods to support population-based cancer research. HMO Research Network Conference, April 16-18, 2013, San Francisco, California.
16. Owens C, Peterson D, Ross T, Buist DSM, Weinmann S, **Kamineni A**, Williams A, Stark A, Adams K, Field T. Effects of transitioning from conventional methods to liquid-based methods on unsatisfactory Pap tests: Results from a multicenter US study. HMO Research Network Conference, April 16-18, 2013, San Francisco, California.
17. Halgrim S, Pham E, **Kamineni A**, Gundersen G, Carrell D, Rutter C. Extracting Signs and Symptoms from Colonoscopy Reports Using NLP. HMO Research Network Conference, April 16-18, 2013, San Francisco, California.
18. Rustagi AS, **Kamineni A**, Weinmann S, Reed SR, Newcomb PA, Etzioni RB, Weiss NS. Efficacy of cervical cancer screening to prevent cervical cancer mortality among women ages 55 to 79 years: A population-based, case-control study. International Cancer Screening Network Conference, October 23-25, 2012, Sydney, Australia.
19. Chubak J, Hubbard R, **Kamineni A**, Wernli K, Rutter CM. Defining and calculating measures of screening participation for international comparative effectiveness research. International Cancer Screening Network Conference. October 23-25, 2012, Sydney, Australia.
20. Chubak J, Rutter CM, **Kamineni A**, Johnson EA, Stout NK, Weiss NS, Doria-Rose VP, Doubeni CA, Buist DSM. Relative effectiveness measures: defining and understanding the essential features for comparative effectiveness research. International Cancer Screening Network Conference. October 23-25, 2012, Sydney, Australia.
21. Weinmann S, Masterson E, Gold H, **Kamineni A**, Williams A, Stout N, Stark A, Field T, Richert-Boe K. Cervical Cancer Testing and Follow-up in Four Managed Care Plans, 1998–2007. HMO Research Network Conference, April 29-May 2, 2012, Seattle, Washington.
22. Adams K, Johnson E, Chubak, J, Doubeni C, **Kamineni A**, Williams A, Weinmann S, Klabunde C, Doria-Rose VP, Rutter C. Development of an algorithm to classify colonoscopy indication using CRN health plan coded data. HMO Research Network Conference, April 29-May 2, 2012, Seattle, Washington.
23. Buist D, Tuzzio L, Greenlee R, Field T, Williams A, Weinmann S, Stout N, **Kamineni A**, Doubeni C. Cancer Screening Guideline Development, Implementation and Dissemination: Connection Points for Researchers and Health Care Delivery Systems for Comparative Effectiveness Research. HMO Research Network Conference, April 29-May 2, 2012, Seattle, Washington.

24. Haque R, Ulcickas Yood M, **Kamineni A**, Avila C, Shi J, Silliman R, Quinn V. 10-year safety of radiotherapy among older breast cancer survivors. HMO Research Network Conference, March 23-25, 2011, Boston, Massachusetts.
25. Mueller BA, Simon MS, Deapen DM, Kelly JM, Cushing KL, Voigt LS, **Kamineni A**, Daling JR. Department of Defense Breast Cancer Research Program: An Era of Hope, October 31-November 4, 1997, Washington DC.
26. Goode EL, **Kamineni A**, Rudolph RE. Risk factors for gastrointestinal anomalies and abdominal wall defects. Third Annual Washington State Joint Conference on Health, September 30-October 2, 1996, Tacoma, Washington.

## PROFESSIONAL ACTIVITIES:

### Manuscript Reviewer

2017	Journal of the National Cancer Institute
2017	Journal of Women's Health
2015 – 2017	Preventive Medicine
2014 – present	Cancer
2012 – present	Cancer Causes and Control
2011 – present	American Journal of Epidemiology

### Membership in Professional Organizations

2014 – present	International Papillomavirus Society
2011 – present	Academy Health
2010 – present	American Society for Preventive Oncology
1999 – present	Society for Epidemiologic Research

### Service

#### National

2019	Member, 2019 International Cancer Screening Network Conference Planning Committee
2018 – 2019	Member, 2019 Health Care Systems Research Network Conference Planning Committee
2016	Abstract reviewer, American Society for Preventive Oncology Annual Meeting

*\*Kaiser Permanente acquired Group Health in February 2017, at which point Group Health Research Institute became Kaiser Permanente Washington Health Research Institute.*

2015 Abstract reviewer, Society for Epidemiologic Research Annual Meeting  
2013 Abstract reviewer, Society for Epidemiologic Research Annual Meeting  
2007 – 2009 Member, Ancillary Studies Committee, The Multi-Ethnic Study of Atherosclerosis

Local

2018 – 2019 Member, Biostatistics Investigator Search Committee, Kaiser Permanente Washington Health Research Institute  
2018 Tennis Team Volunteer, 2018 Special Olympics USA Games, Seattle, Washington  
2014 – 2017 Lead, Cancer Researchers Group, Group Health Research Institute\*  
2016 Member, Mentoring Workgroup, Group Health Research Institute\*  
2014 Member, Mentoring Award Committee, Group Health Research Institute\*  
2012 – 2014 Proposal Reviewer, Partnership for Innovation Program, Group Health Foundation  
1997 – 1998 Senator, Graduate and Professional Student Senate, University of Washington, Seattle, Washington  
1996 – 1997 Student Representative, Department of Epidemiology, University of Washington, Seattle, Washington

*\*Kaiser Permanente acquired Group Health in February 2017, at which point Group Health Research Institute became Kaiser Permanente Washington Health Research Institute.*